On Wednesday, Keryx Biopharmaceuticals (NASDAQ:KERX) made the announcement that two major insurance providers added Auryxia, a drug used to control serum phosphorous levels in patients with …
Maxim Group analyst Jason Kolbert weighed in today with a few insights on Keryx Biopharmaceuticals (NASDAQ:KERX) after the company announced that two national insurance providers have added …
Keryx Biopharmaceuticals (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, announced that two national insurance providers …
On June 22, Brean Capital analyst Jonathan Aschoff weighed in on Keryx Biopharmaceuticals (NASDAQ:KERX) and Rockwell Medical Inc (NASDAQ:RMTI) to provide commentary on …
Keryx Biopharmaceuticals (NASDAQ:KERX) reported a loss of 28 cents per share in the first quarter of 2015, in line with the Zacks Consensus …
Keryx Biopharmaceuticals (NASDAQ:KERX) reported first quarter 2015 earnings on May 4. All eyes were on Auryxia, Keryx’s lead product for patients with chronic …
Keryx Biopharmaceuticals (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, announced its financial results for …
Keryx Biopharmaceuticals (NASDAQ:KERX) announced the appointment of John F. Neylan, MD to the newly created position of Chief Medical Officer.
As the biotech sector becomes more volatile, analyst Joseph Pantginis of Roth Capital points out that it is increasingly necessary to “focus on names with …
Keryx Biopharmaceuticals (NASDAQ:KERX) received more attention from analysts at Roth Capital. The research team, led by analyst Joseph Pantginis, reiterated a Buy rating on the stock with a …
